Evidence map›Paper›PMID 33452561›Full record

Trial reportWorld journal of surgery2021

A Randomized Phase II Study to Evaluate Prolonged Prophylactic Antibacterial Drug Treatment for Patients with Elevated Drain Amylase Concentration After Gastrectomy with D2 Lymph Node Dissection (REDUCED2).

Yuichiro Miki, Masanori Tokunaga, Keita Mori, Norimasa Fukushima, Kazunari Misawa, Kazuhiro Nishikawa, Kazumasa Fujitani, Masaichi Ohira, Yutaka Tanizawa, Etsuro Bando and 1 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Yuichiro MikiDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masanori TokunagaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Keita MoriClinical Trial Coordination Office, Shizuoka Cancer Center, Shizuoka, Japan.
Norimasa FukushimaDepartment of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Kazunari MisawaDepartment of Gastroenterological Surgery, Aichi Cancer Center Chuo Hospital, Nagoya, Japan.
Kazuhiro NishikawaDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Kazumasa FujitaniDepartment of Surgery, Osaka General Medical Center, Osaka, Japan.
Masaichi OhiraDepartment of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Yutaka TanizawaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Etsuro BandoDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan. m.terashima@scchr.jp.
Shizuoka Cancer Center · JPOsaka City University · JPAichi Cancer Center · JPOsaka National Hospital · JPOsaka Prefectural Medical Center · JPTokyo Medical and Dental University · JPYamagata Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAfter D2 gastrectomy for advanced gastric cancer, patients with a high drainage fluid amylase level (d-AMY) on the first postoperative day (1POD) have an especially high risk of severe abdominal infectious complications (AICs), which could be fatal. On the hypothesis that prolonged antibiotic administration could reduce the incidence of severe AICs, we conducted a randomized phase II study to evaluate the optimal treatment duration of prophylactic antibiotics for patients who underwent D2 gastrectomy and had elevated d-AMY on 1POD.

methodsPatients whose d-AMY was >3000 IU/L on 1POD after D2 gastrectomy for gastric cancer were randomly assigned to normal prophylactic antibiotic treatment given only on the day of surgery (Group A) or to prolonged antibiotic treatment given for 1 week after surgery (Group B). The primary endpoint was the incidence of severe AICs (Clavien-Dindo grade IIIa or higher). This trial was registered as UMIN000012152.

resultsThis study was started in December 2013 and stopped in February 2019 because of poor patient accrual. Finally, 35 and 37 patients were assigned to groups A and B, respectively. The incidences of AICs were 22.9% (eight of 35) in group A and 13.5% (five of 37) in group B. One-sided P value of the Fisher exact test was 0.234. No adverse reactions to antibiotic prophylaxis were observed in any of the patients.

conclusionsProlonged prophylactic antibiotic administration had a marginal benefit in preventing grade III or higher AICs and caused no treatment-related morbidities.

Indexed as

Pharmaceutical PreparationsStomach NeoplasmsAmylasesAnti-Bacterial AgentsDrainageGastrectomyHumansLymph Node ExcisionPostoperative ComplicationsAmylasesAnti-Bacterial AgentsPharmaceutical Preparations

Identifiers

PMID33452561
OpenAlexW3121538545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.